Eli Lilly and Company (NYSE:LLY) Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 9.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 202,735 shares of the company’s stock after selling 21,807 shares during the quarter. Eli Lilly and Company accounts for approximately 4.7% of Intech Investment Management LLC’s portfolio, making the stock its 4th biggest holding. Intech Investment Management LLC’s holdings in Eli Lilly and Company were worth $156,511,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Generali Asset Management SPA SGR acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $54,907,000. Evoke Wealth LLC lifted its stake in shares of Eli Lilly and Company by 2.9% during the 4th quarter. Evoke Wealth LLC now owns 7,466 shares of the company’s stock worth $5,764,000 after buying an additional 211 shares during the last quarter. Horizon Investments LLC lifted its stake in shares of Eli Lilly and Company by 64.3% during the 4th quarter. Horizon Investments LLC now owns 8,932 shares of the company’s stock worth $6,896,000 after buying an additional 3,497 shares during the last quarter. Thrivent Financial for Lutherans lifted its stake in shares of Eli Lilly and Company by 9.5% during the 4th quarter. Thrivent Financial for Lutherans now owns 468,736 shares of the company’s stock worth $362,875,000 after buying an additional 40,776 shares during the last quarter. Finally, PDS Planning Inc lifted its stake in shares of Eli Lilly and Company by 1.3% during the 4th quarter. PDS Planning Inc now owns 5,926 shares of the company’s stock worth $4,575,000 after buying an additional 74 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $825.48 on Tuesday. The firm has a market capitalization of $782.70 billion, a PE ratio of 70.49, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. The firm has a fifty day simple moving average of $832.05 and a two-hundred day simple moving average of $841.68. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company announced that its board has initiated a stock buyback program on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

A number of research firms have recently issued reports on LLY. Leerink Partners set a $950.00 target price on shares of Eli Lilly and Company in a research note on Friday, January 17th. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Morgan Stanley set a $1,146.00 price target on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Finally, Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,009.72.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.